PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33404998-1	2021	Modestly elevated circulating levels of the ketone beta-hydroxybutyrate (betaOHB) during treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors cause different beneficial effects on organs and cells, depending on the succinyl-CoA:3-ketoacid CoA transferase (SCOT) level.	3-Hydroxybutyric Acid	51-71	3-oxoacid CoA-transferase 1	Homo sapiens	227-266	
33404998-1	2021	Modestly elevated circulating levels of the ketone beta-hydroxybutyrate (betaOHB) during treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitors cause different beneficial effects on organs and cells, depending on the succinyl-CoA:3-ketoacid CoA transferase (SCOT) level.	3-Hydroxybutyric Acid	51-71	3-oxoacid CoA-transferase 1	Homo sapiens	268-272	
33281976-10	2021	Both cell lines expressed the enzymes (OXCT1/2, BDH1 and ACAT1/2) responsible for metabolizing BHB to acetyl-CoA, yet expression of these enzymes was not altered by either glucose deprivation or BHB treatment.	3-Hydroxybutyric Acid	95-98	3-oxoacid CoA-transferase 1	Homo sapiens	39-46	
31960270-2	2020	Modestly elevated circulating beta-hydroxybutyrate (betaOHB) during treatment with SGLT2 inhibitors causes different beneficial effects on organs and cells, depending on succinyl-CoA:3-ketoacid CoA transferase (SCOT) levels.	3-Hydroxybutyric Acid	30-50	3-oxoacid CoA-transferase 1	Homo sapiens	170-209	
31960270-2	2020	Modestly elevated circulating beta-hydroxybutyrate (betaOHB) during treatment with SGLT2 inhibitors causes different beneficial effects on organs and cells, depending on succinyl-CoA:3-ketoacid CoA transferase (SCOT) levels.	3-Hydroxybutyric Acid	30-50	3-oxoacid CoA-transferase 1	Homo sapiens	211-215